Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Smart Dairy Farming Aanpak Requirements-analyse (Eisen en Wensen)

Het doel van het project Smart Dairy Farming (SDF) is het ondersteunen van melkveehouders bij de verzorging van individuele dieren, om daarmee een goede gezondheid, een langer leven en een langere productietijd van de koe te bewerkstelligen. Daartoe ontwikkelt Smart Dairy Farming sensoren en andere technologische hulpmiddelen, beslismodellen, procesbeschrijvingen en adviesproducten. Deze hulpmiddelen en diensten stellen melkveehouders in staat betere keuzes te maken op het gebied van gezondheid, vruchtbaarheid en voeding

Smart Dairy Farming Aanpak Requirements-analyse (Eisen en Wensen) : SDF Eisen en Wensen 1.0

Het doel van het project Smart Dairy Farming (SDF) is het ondersteunen van melkveehouders bij de verzorging van individuele dieren, om daarmee een goede gezondheid, een langer leven en een langere productietijd van de koe te bewerkstelligen. Daartoe ontwikkelt Smart Dairy Farming sensoren en andere technologische hulpmiddelen, beslismodellen, procesbeschrijvingen en adviesproducten. Deze hulpmiddelen en diensten stellen melkveehouders in staat betere keuzes te maken op het gebied van gezondheid, vruchtbaarheid en voeding

Smart Dairy Farming Aanpak Requirements-analyse (Eisen en Wensen) : Persona’s en UseCases

Het doel van het project Smart Dairy Farming (SDF) is het ondersteunen van melkveehouders bij de verzorging van individuele dieren, om daarmee een goede gezondheid, een langer leven en een langere productietijd van de koe te bewerkstelligen. Daartoe ontwikkelt Smart Dairy Farming sensoren en andere technologische hulpmiddelen, beslismodellen, procesbeschrijvingen en adviesproducten. Deze hulpmiddelen en diensten stellen melkveehouders in staat betere keuzes te maken op het gebied van gezondheid, vruchtbaarheid en voeding

EMPOWER. Deliverable no 3.2 Business model methodology

Based on EMPOWER Deliverable 3.1 and the use of complimenting resources, a Business Model Methodology is outlined in this deliverable in order to support and organize the work effort that should be performed to develop sound business models for the services that should be tested in four Living Lab Cities participating in the project. This deliverable includes an account how the methodology has driven the organization of the modelling work that will be performed at a later stage in the project and consequently provide input to both other tasks within WP3 as wells as tasks in other Work Packages

EMPOWER. Deliverable no 3.1 International review of business models and best practice

Through a literature and case study review ten key success factors to support the design and implementation of incentive-scheme based business models within EMPOWER promoting reduction of CFV use were identified, which will provide input to both other tasks within WP 3 as wells as tasks in other Work Packages

Ecodriver. D12.2: Multi-modal in-vehicle and nomadic device eco-driving support for car drivers

This deliverable provides a report of the work conducted in Work Package 12: eco-driving system development and HMI feedback. The tasks required development of simple eco-driving feedback model algorithms and test scenarios and an assessment of basic systems and feedback modalities. These assessments have been conducted both in the laboratory and the simulated vehicle environment. The output of this stage of the ecoDriver project has been used to inform the design of Work Package 13 studies which are focused on the evaluation of eco-driving feedback solutions. This Work Package represents an important stage in the design of the final ecoDriver system, which is currently being prepared for in-vehicle integration and on-road testing